Michael Davidson

Dr. Michael H.
Davidson, MD, is an Independent Director at BioAge Labs, Inc., a Chief Executive Officer & Director at NewAmsterdam Pharma Co. NV, an Independent Director at Tenax Therapeutics, Inc., a Chief Executive Officer & Executive Director at NewAmsterdam Pharma BV, a Chief Executive Officer & Executive Director at NewAmsterdam Pharma Corp., a Chief Executive Officer & Executive Director at NewAmsterdam Pharma Holding BV, a Professor at The University of Chicago Department of Medicine, a Chairman at SonoThera, Inc., a Director-Lipid Clinic & Professor at The University of Chicago, a Member at American College of Cardiology Foundation and a Member at American College of Chest Physicians.
He is on the Board of Directors at BioAge Labs, Inc., NewAmsterdam Pharma Co. NV, Abcentra, Inc., Tenax Therapeutics, Inc., Jocasta Neuroscience, Inc., Inositec AG, NewAmsterdam Pharma BV, NewAmsterdam Pharma Corp., NewAmsterdam Pharma Holding BV, Midwest Lipid Association, NanoPhoria Srl, Preventive Cardiology Institute, Inc. and Sonogene LLC.
Dr. Davidson was previously employed as an Independent Non-Executive Director by Silence Therapeutics Plc, a Director & Chief Scientific Officer by Trofi Nutritionals, Inc., an Independent Director by Caladrius Biosciences, Inc., a Chief Scientific & Medical Officer by Corvidia Therapeutics, Inc., an Independent Director by ABIONYX Pharma SA, a President by National Lipid Association, a Chief Medical Officer & Executive Vice President by Omthera Pharmaceuticals, Inc., and a President & Chief Executive Officer by Chicago Center for Clinical Research.
He also served on the board at Cerenis Therapeutics, Inc. He received his undergraduate degree from Northwestern University and a doctorate degree from The Ohio State University College of Medicine.